Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3854103 | 0.86 | MEN1 (0.61) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL19979299 | 0.84 | MEN1 (0.59) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL19979294 | 0.84 | MEN1 (0.55) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL3855001 | 0.84 | MEN1 (0.64) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL19979295 | 0.83 | MEN1 (0.57) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL21726067 | 0.83 | MEN1 (0.57) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL3853544 | 0.82 | MEN1 (0.56) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL28688739 | 0.82 | MEN1 (0.56) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL29093446 | 0.82 | MEN1 (0.56) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL29093251 | 0.82 | MEN1 (0.56) | MEN1PABPC1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912709-B2 | Temozolomide compounds, polymers prepared therefrom, and method of treating a disease | UNIVERSITY OF MASSACHUSETTS (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912709-B2 | Temozolomide compounds, polymers prepared therefrom, and method of treating a disease | UNIVERSITY OF MASSACHUSETTS (US) | 2024-02-27 | — | — | US | disclosed |
| US-20210198265-A1 | TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE | UNIVERSITY OF MASSACHUSETTS | 2021-07-01 | — | — | US | disclosed |
| US-10995094-B2 | Temozolomide compounds, polymers prepared therefrom, and method of treating a disease | THE UNIVERSITY OF MASSACHUSETTS (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200140448-A1 | TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE | NATIONAL SCIENCE FOUNDATION | 2020-05-07 | — | — | US | disclosed |
| US-10562901-B2 | Temozolomide compounds, polymers prepared therefrom, and method of treating a disease | THE UNIVERSITY OF MASSACHUSETTS (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180079754-A1 | TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE | NATIONAL SCIENCE FOUNDATION | 2018-03-22 | — | — | US | disclosed |
| US-20180079754-A1 | TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE | NATIONAL SCIENCE FOUNDATION | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912709-B2 | Temozolomide compounds, polymers prepared therefrom, and method of treating a disease | PBRM1, MGMT, TOP1 | MEN1 5/4885PABPC1 1794/4885KMT2A 401/4885 |
| US-20210198265-A1 | TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE | PBRM1, MGMT, TOP1 | MEN1 5/4885PABPC1 1794/4885KMT2A 401/4885 |
| US-20200140448-A1 | TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE | PBRM1, MGMT, TOP1 | MEN1 5/4885PABPC1 1794/4885KMT2A 401/4885 |
| US-10562901-B2 | Temozolomide compounds, polymers prepared therefrom, and method of treating a disease | PBRM1, MGMT, TOP1 | MEN1 5/4885PABPC1 1794/4885KMT2A 401/4885 |
| US-20180079754-A1 | TEMOZOLOMIDE COMPOUNDS, POLYMERS PREPARED THEREFROM, AND METHOD OF TREATING A DISEASE | PBRM1, MGMT, TOP1 | MEN1 5/4885PABPC1 1794/4885KMT2A 401/4885 |
| US-10995094-B2 | Temozolomide compounds, polymers prepared therefrom, and method of treating a disease | PBRM1, MGMT, TOP1 | MEN1 5/4885PABPC1 1794/4885KMT2A 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.